Polaris Partners and Mithril Capital led a $50m Series A round in Adagio Therapeutics, a biotechnology company, with participation from Fidelity funds, OrbiMed, M28 Capital and GV. "The technical differentiation and quality of Adagio’s work represents a major step forward for the field and generated overwhelming investor interest at a pivotal moment in our fight against the SARS-CoV-2 pandemic. We were impressed by Adagio’s unique strategy and the truly differentiated nature of its antibodies, which we believe can deliver benefits over the near and long-term as society continues to battle the risks associated with coronavirus outbreaks," Marc Elia, M28 Capital Founder.